- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Salk Scientists Want to Target the Protein Interactome for Drug Discovery
The study, published in Cell Reports, evaluates the dynamic protein interactions that promote different diseases including cancer. By capturing these interactions, the authors hope to discover new drug targets.
For decades, researchers have struggled to translate basic scientific discoveries about cancer into therapeutics that effectively—and with minimal side effects—shrink a tumor.
One avenue that may hold great potential is the development of drugs that interfere with interactions between proteins, which are often disrupted during the formation and spread of cancer. Deciphering these interactions, however, has proven difficult and time consuming, leading to doubts about the practicality of this approach as a route to new therapies.
Cell Reports
Now, Salk scientists have developed a highly sensitive, new method that enables them to detect fleeting protein interactions that play critical roles in the development of many diseases including cancer. The approach, published November 20 in , could dramatically accelerate the identification of many potential new drug targets and provide an immediate platform to screen for badly needed new drug candidates that disrupt abnormal protein interactions.
Read the complete article on MedicalXpress: http://bit.ly/1zJAAr4
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
